Histology Depending on the histological appearances, mitotic and proliferation www.selleckchem.com/products/INCB18424.html indices, GICTs are classified as well differentiated neuroendocrine tumours, well differentiated endocrine carcinomas, poorly differentiated endocrine carcinomas and mixed exocrine/endocrine tumours (47). Proliferation index is assessed using immunostaining with Ki67 antibody

and is usually low (<2%) in classical MCs. Whilst 85% of all MCs and their metastases react to chromogranin A and synaptophysin (Figure 3) positive immunoreactivity to serotonin on the other hand, Inhibitors,research,lifescience,medical implies that the primary tumour originates from the midgut (2,48). Treatment Surgery continues to be the main modality of treatment for GICTs with a potential to cure in early stage

disease and providing best palliation in those with advanced disease. Whilst the type and nature of surgery depends on the site and extent of Inhibitors,research,lifescience,medical the primary lesion, it is important to note that most patients with MCs are subjected to laparotomy without the awareness Inhibitors,research,lifescience,medical of a diagnosis of carcinoid tumour. Usually a wedge resection including the bowel segment containing the primary tumour and the involved lymph nodes are excised; this procedure is also indicated in those patients with synchronous liver metastases, as local disease if left untreated can lead to significant morbidity (2). Despite curative primary surgery, 80% of patients with MCs develop recurrence and these are usually evident after a median follow up of 5-10 years (3). The recurrent disease plus mesenteric fibrosis can manifest as chronic abdominal pain, intestinal obstruction and/or bowel ishaemia necessitating further surgical intervention (49,50) but earlier Inhibitors,research,lifescience,medical diagnosis Inhibitors,research,lifescience,medical of the recurrence can often be accomplished by serial estimation of serum chromogranin A levels (10). Recently prophylactic surgery to remove mesenterico-intestinal tumour in asymptomatic patients has been advocated because patients who receive and survive medical treatment can still present with major intra-abdominal complications from the mesenteric

disease (2). Pre-operative mapping of the extent of the disease within the mesentery and assessment of the involvement of the root of the major mesenteric vessels with dynamic CT scan these is now considered mandatory in treatment planning. Tumour debulking in patients with advanced mesenteric metastases in the absence of liver metastases has been reported to achieve a 5-year survival of 91% (with a median survival of 12.4 years) (51). Operating on patients with carcinoid syndrome can induce carcinoid crisis (hyperthermia, shock, arrhythmia, excessive flush and bronchial spasm) and as a prophylaxis, it is important for these patients to be given intravenous octreotide (500 μg in 500 mL saline, 50 mL/hour) during surgery.